title: Safety measures of L-carnitine L-tartrate supplementation in healthy men.
abstract: The purpose of this investigation was to examine the effects of ingestion of L-CARNIPURE (L-carnitine L-tartrate [LCLT]) on alterations in a complete blood cell profile and in circulating metabolic enzymes. Using a balanced, placebo (P), cross-over design (1 week washout), 10 healthy, active men volunteered and acted as their own control taking either a P or LCLT supplement (3 g.day(-1)) for 3 weeks. Postabsorptive morning blood samples were obtained both before and after 21 days of P and LCLT supplementation. Serum samples were analyzed for clinical chemistries including a complete chemistry panel with markers of liver and renal function along with various minerals and electrolytes. In addition, whole blood was analyzed for a complete blood count with differential. It was determined that there were no statistically significant differences between the LCLT and the placebo conditions for any of the variables examined. The results of this study suggest that LCLT, when used as a dietary supplement, has no adverse effects on metabolic and hematological safety variables in normally healthy men.
authors.affiliation: The Human Performance Laboratory, Department of Kinesiology, University of Connecticut, Storrs, CT 06269, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Rubin
authors.forename: J S
authors.initials: JS
authors.lastname: Volek
authors.forename: A L
authors.initials: AL
authors.lastname: Gómez
authors.forename: N A
authors.initials: NA
authors.lastname: Ratamess
authors.forename: D N
authors.initials: DN
authors.lastname: French
authors.forename: M J
authors.initials: MJ
authors.lastname: Sharman
authors.forename: W J
authors.initials: WJ
authors.lastname: Kraemer
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001769:Blood / Q000187:drug effects; D002331:Carnitine / Q000008:administration & dosage / Q000009:adverse effects*; D018592:Cross-Over Studies; D019587:Dietary Supplements / Q000009:adverse effects*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004573:Electrolytes / Q000097:blood; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007677:Kidney Function Tests; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D008670:Metals / Q000097:blood; D010758:Phosphorus / Q000097:blood; D012016:Reference Values; D013644:Tartrates / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D015415:Biomarkers; D004338:Drug Combinations; D004573:Electrolytes; D008670:Metals; D013644:Tartrates; D010758:Phosphorus; D002331:Carnitine